What is the role of plasma exchange in the management of adult immune thrombocytopenia (ITP)?

Role of Plasma Exchange in Adult Immune Thrombocytopenia (ITP)

Plasma exchange is not a standard or recommended therapy for adult ITP and is not included in evidence-based treatment guidelines. 1

Guideline-Based Treatment Framework

The American Society of Hematology 2019 guidelines and the International Consensus Report comprehensively outline first-line and second-line therapies for adult ITP, and plasma exchange is notably absent from these recommendations. 1

Standard First-Line Therapies Include:

• Corticosteroids (prednisone, dexamethasone, methylprednisolone) 1
• Intravenous immunoglobulin (IVIg) 1
• Anti-D immunoglobulin (for Rh-positive, non-splenectomized patients) 1

Standard Second-Line Therapies Include:

• Splenectomy 1
• Rituximab 1
• Thrombopoietin receptor agonists (romiplostim, eltrombopag) 1
• Immunosuppressive agents (azathioprine, cyclosporin A, cyclophosphamide, mycophenolate mofetil) 1

Limited Role in Exceptional Circumstances

Plasma exchange has been classified as a Category III indication (uncertain benefit-to-risk ratio) by the American Society for Apheresis for ITP management. 2

When Plasma Exchange Has Been Attempted:

Refractory ITP with life-threatening bleeding or surgical emergencies:

• Used in patients who have failed all conventional therapies 3, 4, 5
• Typically reserved for the highest severity of illness cases 2
• Most effective when combined with platelet transfusion in hemorrhagic emergencies 4

Clinical Reality from National Data:

• Only 0.66% of ITP hospitalizations involved plasma exchange (2010-2014 U.S. data) 2
• Used predominantly in patients with major or extreme severity of illness 2
• Associated with significantly longer hospital stays and higher comorbidity burden 2

Proposed Mechanism When Used:

• Theoretically removes antiplatelet antibodies from circulation 3, 4, 6
• May temporarily reduce platelet destruction 4
• Historical case reports suggest combining plasma exchange with IVIg in patients who became refractory to IVIg alone 6

Critical Limitations and Caveats

Lack of sustained benefit:

• Responses are typically short-lived (approximately 2 weeks) 6
• Patients often develop resistance after repeated treatments 6
• No evidence of durable remission 3, 5

Patient selection matters:

• Historical data suggest plasma exchange may only work in patients who initially responded to IVIg before becoming refractory 6
• Patients without initial IVIg response did not benefit from combined plasma exchange and IVIg therapy 6

Common pitfall: Do not confuse ITP with immune thrombotic thrombocytopenic purpura (iTTP), where plasma exchange is the cornerstone of therapy and life-saving. 7, 8 iTTP presents with thrombocytopenia plus microangiopathic hemolytic anemia and severely deficient ADAMTS13 activity (<10%), requiring urgent plasma exchange. 8

Practical Clinical Algorithm

For newly diagnosed ITP:

• Use corticosteroids, IVIg, or anti-D per guidelines 1
• Do not use plasma exchange 1

For chronic refractory ITP:

• Proceed through standard second-line options (splenectomy, rituximab, TPO-receptor agonists, immunosuppressives) 1
• Do not routinely use plasma exchange 1

For refractory ITP with life-threatening bleeding requiring emergency surgery:

• Consider plasma exchange combined with platelet transfusion only as a last resort 4
• Recognize this is based on case reports, not controlled trials 4, 5
• Expect only temporary benefit requiring immediate definitive surgical intervention 4